Affibody, General Electric deal

Affibody partnered with General Electric's GE Healthcare unit to develop a PET imaging agent for breast and gastric cancer that targets epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2; neu). The partners expect to begin clinical trials this year. They plan to investigate the confirmation of HER2 status in patients with breast cancer recurrence; to determine if HER2 status changes over time; to monitor therapy of patients with metastatic breast cancer receiving anti-HER2 treatments; and to help resolve indeterminate HER2 tests. Details were not disclosed. ...